Inclusion Criteria:

• Patients with autoinflammatory diseases aged >12 years and followed in the CEREMAIA internal medicine department present for consultation or day hospital for a routine care visit.

• FMF defined by the Eurofever/PRINTO criteria

• or CAPS définie by the Eurofever/PRINTO criteria

• or MKD defined by the Eurofever/PRINTO criteria

• or - DADA2 defined by the presence of two mutations in the ADA2 gene with pathogenicity of at least ≥ 3

• or - HA20 defined by the presence of one TNFAIP3 mutation with pathogenicity of at least ≥ 3

• or - JAAD defined by the presence of one JAK1 mutation with pathogenicity of at least ≥ 3

• or Juvenile polyarthritis defined by the presence of one LACC1 mutation with pathogenicity of at least ≥ 3

• or - Unclassified AMI defined by:

  • Fever +/- systemic symptoms Recurrent
  • Biological inflammation (CRP>20mg/l) in crisis or permanent
  • Absence of pathogenic mutation highlighted by current next-generation sequencing techniques in known autoinflammatory disease genes

• Collection of non-opposition to participation in research and specific consent for the biological collection of the patient or their legal representative in the case of a minor patient

• Lack of legal protection

• Patients benefiting from a social security scheme

Exclusion Criteria:

• Antibiotic therapy within 3 months prior to inclusion. If antibiotic therapy was initiated between inclusion and stool collection (data collected on the self-administered questionnaire accompanying the stool collection), the analysis data performed prior to antibiotic therapy will be retained, and the stool will not be analyzed.
• Current infection on the day of inclusion
• No social security
• Refusal to participate